Современные клинические рекомендации по ведению пациентов с эозинофильным эзофагитом

В статье представлен анализ современных клинических рекомендаций по ведению пациентов с эозинофильным эзофагитом (ЭоЭ) — хроническим иммуноопосредованным заболеванием пищевода, характеризующимся эозинофильной инфильтрацией слизистой оболочки (≥ 15 эоз./п.зр.) и клиническими проявлениями дисфункции пищевода. Освещены ключевые изменения в диагностике, рассматриваются современные подходы к лечению: диетотерапия (начиная с наименее ограничительных диет), фармакологическое лечение (ингибиторы протонной помпы, топические глюкокортикоиды, биологическая терапия) и эндоскопическая дилатация при стриктурах. Авторами подчеркивается необходимость комплексного мониторинга (клинического, эндоскопического и гистологического) для оценки ответа на терапию и длительного поддерживающего лечения ввиду хронического характера заболевания. Отдельное внимание уделено аспектам ведения педиатрических пациентов.

1. Dhar A, Haboubi HN, Attwood SE, et al. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut. 2022;71(8):1459–1487. doi: https://doi.org/10.1136/gutjnl-2022-327326

2. Ивашкин В.Т., Баранская Е.К., Кайбышева В.О. и др. Клинические рекомендации по диагностике и лечению эозинофильного эзофагита. — М.; 2013. — 38 с.

3. Кайбышева В.О., Михалева Л.М., Федоров Е.Д. и др. Эозинофильный эзофагит. — М.: Издательство «Медиа Сфера»; 2024. — 180 с.

4. Кайбышева В.О., Драпкина О.М., Маев И.В. и др. Диагностика и лечение эозинофильного эзофагита: методические рекомендации. — М.: ООО Силицея-Полиграф; 2024. — 58 с.

5. Кайбышева В.О., Михалева Л.М., Никонов Е.Л., Шаповальянц С.Г. Эпидемиология, этиология и патогенез эозинофильного эзофагита. Новейшие данные // Доказательная гастроэнтерология. — 2019. — Т. 8. — № 2. — С. 50–72. — doi: https://doi.org/10.17116/dokgastro2019802150

6. Arias A, Perez-Martinez I, Tenias JM, Lucendo AJ. Systematic review with meta-analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2016;43(1):3–15. doi: https://doi.org/10.1111/apt.13441

7. van Rhijn BD, Verheij J, Smout AJ, Bredenoord AJ. Rapidly increasing incidence of eosinophilic esophagitis in a large cohort. Neurogastroenterol Motil. 2013;25(1):47–52.e5. doi: https://doi.org/10.1111/nmo.12009

8. Warners M, de Rooij WE, Van Rhijn BD, et al. Large Increase in Incidence of Eosinophilc Esophagitis Over the Last 20 Years in the Netherlands: Results from a Nationwide Pathology Database. Gastroenterology. 2017;152(5):862–863. doi: https://doi.org/10.1016/S0016-5085(17)32964-5

9. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med. 2004;351(9):940–941. doi: https://doi.org/10.1056/NEJM200408263510924

10. Hahn JW, Lee K, Shin JI, et al. Global Incidence and Prevalence of Eosinophilic Esophagitis, 1976-2022: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21(13):3270– 3284.e77. doi: https://doi.org/10.1016/j.cgh.2023.06.005

11. Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335–358. doi: https://doi.org/10.1177/2050640616689525

12. Gomez Torrijos E, Gonzalez-Mendiola R, Alvarado M, et al. Eosinophilic Esophagitis: Review and Update. Front Med (Lausanne). 2018;5:247. doi: https://doi.org/10.3389/fmed.2018.00247

13. Barni S, Arasi S, Mastrorilli C, et al. Pediatric eosinophilic esophagitis: a review for the clinician. Ital J Pediatr. 2021;47(1):230. doi: https://doi.org/10.1186/s13052-021-01178-2

14. Blanchard C, Stucke EM, Rodriguez-Jimenez B, et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol. 2011;127(1):208–217, 217.e1–e7. doi: https://doi.org/10.1016/j.jaci.2010.10.039

15. Jensen ET, Kuhl JT, Martin LJ, et al. Prenatal, intrapartum, and postnatal factors are associated with pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2018;141(1):214–222. doi: https://doi.org/10.1016/j.jaci.2017.05.018

16. Dhaliwal J, Tobias V, Sugo E, et al. Eosinophilic esophagitis in children with esophageal atresia. Dis Esophagus. 2014;27(4):340–347. doi: https://doi.org/10.1111/dote.12119

17. Blanchard C, Stucke EM, Burwinkel K, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol. 2010;184(7):4033–4041. doi: https://doi.org/10.4049/jimmunol.0903069

18. Валитова Э.Р., Эмбутниекс Ю.В., Березина О.И. и др. Эозинофильный эзофагит // Экспериментальная и клиническая гастроэнтерология. — 2018. — № 10. — 115–119. — doi: https://doi.org/10.31146/1682-8658-ecg-158-10-115-119

19. Thel HL, Anderson C, Xue AZ, et al. Prevalence and Costs of Eosinophilic Esophagitis in the United States. Clin Gastroenterol Hepatol. 2025;23(2):272–280.e8. doi: https://doi.org/10.1016/j.cgh.2024.09.031

20. Prasad GA, Alexander JA, Schleck CD, et al. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2009;7(10):1055–1061. doi: https://doi.org/10.1016/j.cgh.2009.06.023

21. Syed AA, Andrews CN, Shaffer E, et al. The rising incidence of eosinophilic oesophagitis is associated with increasing biopsy rates: a population-based study. Aliment Pharmacol Ther. 2012;36(10):950–958. doi: https://doi.org/10.1111/apt.12053

22. Dellon ES, Erichsen R, Baron JA, et al. The increasing incidence and prevalence of eosinophilic oesophagitis outpaces changes in endoscopic and biopsy practice: national population-based estimates from Denmark. Aliment Pharmacol Ther. 2015;41(7):662– 670. doi: https://doi.org/10.1111/apt.13129

23. Giriens B, Yan P, Safroneeva E, et al. Escalating incidence of eosinophilic esophagitis in Canton of Vaud, Switzerland, 19932013: a population-based study. Allergy. 2015;70(12):1633–1639. doi: https://doi.org/10.1111/all.12733

24. Straumann A, Simon HU. Eosinophilic esophagitis: escalating epidemiology? J Allergy Clin Immunol. 2005;115(2):418–419. doi: https://doi.org/10.1016/j.jaci.2004.11.006

25. Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedingsofthe AGREEConference. Gastroenterology. 2018;121(3):281–284. doi: https://doi.org/10.1053/j.gastro.2018.07.009.

26. Young E, Philpott H. Pathophysiology of Dysphagia in Eosinophilic Esophagitis: Causes, Consequences, and Management. Dig Dis Sci. 2022;67(4):1101–1115. doi: https://doi.org/10.1007/s10620-022-07419-6

27. O’Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of Eosinophilic Esophagitis. Gastroenterology. 2018;154(2):333–345. doi: https://doi.org/10.1053/j.gastro.2017.06.065

28. Shoda T, Wen T, Aceves SS, et al. Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. Lancet Gastroenterol Hepatol. 2018;3(7):477–488. doi: https://doi.org/10.1016/S2468-1253(18)30096-7

29. Keely S, Talley NJ. Endophenotyping eosinophilic oesophagitis: a new era for management? Lancet Gastroenterol Hepatol. 2018;3(7):449–450. doi: https://doi.org/10.1016/S2468-1253(18)30134-1

30. Dellon ES, Khoury P, Muir AB, et al. A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. Gastroenterology. 2022;163(1):59–76. doi: https://doi.org/10.1053/j.gastro.2022.03.025

31. Straumann A, Aceves SS, Blanchard C, et al. Pediatric and adult eosinophilic esophagitis: similarities and differences. Allergy. 2012;67(4):477–490. doi: https://doi.org/10.1111/j.1398-9995.2012.02787.x

32. Lucendo AJ, Friginal-Ruiz AB, Rodriguez B. Boerhaave’s syndrome as the primary manifestation of adult eosinophilic esophagitis. Two case reports and a review of the literature. Dis Esophagus. 2011;24(2):E11–E15. doi: https://doi.org/10.1111/j.1442-2050.2010.01167.x

33. Jackson WE, Mehendiratta V, Palazzo J, et al. Boerhaave’s syndrome as an initial presentation of eosinophilic esophagitis: a case series. Ann Gastroenterol. 2013;26(2):166–169.

34. Straumann A, Katzka DA. Diagnosis and Treatment of Eosinophilic Esophagitis. Gastroenterology. 2018;154(2):346–359. doi: https://doi.org/10.1053/j.gastro.2017.05.066

35. Straumann A, Bussmann C, Zuber M, et al. Eosinophilic esophagitis: analysis of food impaction and perforation in 251 adolescent and adult patients. Clin Gastroenterol Hepatol. 2008;6(5):598–600. doi: https://doi.org/10.1016/j.cgh.2008.02.003

36. Dellon ES, Muir AB, Katzka DA, et al. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis. Am J Gastroenterol. 2025;120(1):31–59. doi: https://doi.org/10.14309/ajg.0000000000003194

37. Amil-Dias J, Oliva S, Papadopoulou A, et al. Diagnosis and management of eosinophilic esophagitis in children: An update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2024;79(2):394–437. doi: https://doi.org/10.1002/jpn3.12188

38. Oliva S, Arrigo S, Bramuzzo M, et al. Eosinophilic esophagitis in children and adolescents: a clinical practice guideline. Ital J Pediatr. 2025;51(1):242. doi: https://doi.org/10.1186/s13052025-02056-x

39. Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108(5):679–692; quiz 693. doi: https://doi.org/10.1038/ajg.2013.71

40. Ивашкин В.Т., Баранская Е.К., Кайбышева В.О. и др. Эозинофильный эзофагит: обзор литературы и описание собственного наблюдения // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. — 2012. — Т. 22. — № 1. — С. 71–81.

41. Dellon ES, Gibbs WB, Fritchie KJ, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009;7(12):1305–1313; quiz 1261. doi: https://doi.org/10.1016/j.cgh.2009.08.030

42. Remedios M, Campbell C, Jones DM, et al. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc. 2006;63(1):3–12. doi: https://doi.org/10.1016/j.gie.2005.07.049

43. Croese J, Fairley SK, Masson JW, et al. Clinical and endoscopic features of eosinophilic esophagitis in adults. Gastrointest Endosc. 2003;58(4):516–522. doi: https://doi.org/10.1067/s0016-5107(03)01870-4

44. Kahn J, Bussmann C, Beglinger C, et al. Exercise-induced chest pain: an atypical manifestation of eosinophilic esophagitis. Am J Med. 2015;128(2):196–199. doi: https://doi.org/10.1016/j.amjmed.2014.08.007

45. Hudgens S, Evans C, Phillips E, Hill M. Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension. J Patient Rep Outcomes. 2017;1(1):3. doi: https://doi.org/10.1186/s41687017-0006-5

46. Hirano I. Role of advanced diagnostics for eosinophilic esophagitis. Dig Dis. 2014;32(1-2):78–83. doi: https://doi.org/10.1159/000357014

47. Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013;62(4):489–495. doi: https://doi.org/10.1136/gutjnl-2011-301817

48. Warners MJ, Hindryckx P, Levesque BG, et al. Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. Am J Gastroenterol. 2017;112(11):1658–1669. doi: https://doi.org/10.1038/ajg.2017.363

49. Gentile N, Katzka D, Ravi K, et al. Oesophageal narrowing is common and frequently under-appreciated at endoscopy in patients with esophageal eosinophilia. Aliment Pharmacol Ther. 2014;40(1112):1333–1340. doi: https://doi.org/10.1111/apt.12977

50. Nelson MJ, Miller FH, Moy N, et al. Comparison of endoscopy and radiographic imaging for detection of esоphageal inflammation and remodeling in adults with eosinophilic esophagitis. Gastrointest Endosc. 2018;87(4):962–968. doi: https://doi.org/10.1016/j.gie.2017.09.037

51. Hassan M, Aceves S, Dohil R, et al. Esophageal compliance quantifies epithelial remodeling in pediatric patients with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2019;68(4):559–565. doi: https://doi.org/10.1097/MPG.0000000000002202

52. Cotton CC, Woosley JT, Moist SE, et al. Determination of a treatment response threshold for the eosinophilic esophagitis endoscopic reference score. Endoscopy. 2022;54(7):635–643. doi: https://doi.org/10.1055/a-1675-7860

53. Collins MH, Martin LJ, Alexander ES, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30(3):1–8. doi: https://doi.org/10.1111/dote.12470

54. Muir A, Falk GW. Eosinophilic Esophagitis: A Review. JAMA. 2021;326(13):1310–1318. doi: https://doi.org/10.1001/jama.2021.14920

55. Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc. 2006;64(3):313–319. doi: https://doi.org/10.1016/j.gie.2006.04.037

56. Shah A, Kagalwalla AF, Gonsalves N, et al. Histopathologic variability in children with eosinophilic esophagitis. Am J Gastroenterol. 2009;104(3):716–721. doi: https://doi.org/10.1038/ajg.2008.117

57. Peery AF, Cao H, Dominik R, et al. Variable reliability of endoscopic findings with white-light and narrow-band imaging for patients with suspected eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2011;9(6):475–480. doi: https://doi.org/10.1016/j.cgh.2011.02.026

58. Dellon ES, Speck O, Woodward K. The patchy nature of esophageal eosinophilia in eosinophilic esophagitis: Insights from pathology samples from a clinical trial. Gastroenterology. 2012;142(Suppl):S-432. doi: https://doi.org/10.1016/S00165085(12)61626-6

59. DeBrosse CW, Collins MH, Buckmeier Butz BK, et al. Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982–1999. J Allergy Clin Immunol. 2010;126(1):112–119. doi: https://doi.org/10.1016/j.jaci.2010.05.027

60. Kim HP, Vance RB, Shaheen NJ, et al. The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(9):988–996. doi: https://doi.org/10.1016/j.cgh.2012.04.019

61. Kerlin P, Jones D, Remedios M, Campbell C. Prevalence of eosinophilic esophagitis in adults with food bolus obstruction of the esophagus. J Clin Gastroenterol. 2007;41(4):356–361. doi: https://doi.org/10.1097/01.mcg.0000225590.08825.77

62. Byrne KR, Panagiotakis PH, Hilden K, et al. Retrospective Analysis of Esophageal Food Impaction: Differences in Etiology by Age and Gender. Dig Dis Sci. 2007;52(3):717–721. doi: https://doi.org/10.1007/s10620-006-9499-0

63. Kirchner GI, Zuber-Jerger I, Endlicher E, et al. Causes of bolus impaction in the esophagus. Surg Endosc. 2011;25(10):3170– 3174. doi: https://doi.org/10.1007/s00464-011-1681-6

64. Sperry SL, Crockett SD, Miller CB, et al. Esophageal foreignbody impactions: epidemiology, time trends, and the impact of the increasing prevalence of eosinophilic esophagitis. Gastrointest Endosc. 2011;74(5):985–991. doi: https://doi.org/10.1016/j.gie.2011.06.029

65. Hurtado CW, Furuta GT, Kramer RE. Etiology of esophageal food impactions in children. J Pediatr Gastroenterol Nutr. 2011;52(1):43–46. doi: https://doi.org/10.1097/MPG.0b013e3181e67072

66. Diniz LO, Towbin AJ. Causes of Esophageal Food Bolus Impaction in the Pediatric Population. Dig Dis Sci. 2011;57(3):690–693. doi: https://doi.org/10.1007/s10620-011-1911-8

67. Heerasing N, Lee SY, Alexander S, Dowling D. Prevalence of eosinophilic oesophagitis in adults presenting with oesophageal food bolus obstruction. World J Gastrointest Pharmacol Ther. 2015;6:244–247. https://doi.org/10.4292%2Fwjgpt.v6.i4.244

68. Philpott H, Nandurkar S, Thien F, et al. Seasonal Recurrence of Food Bolus Obstruction in Eosinophilic Esophagitis. Intern Med J. 2015;45(9):939–943. doi: https://doi.org/10.1111/imj.12790

69. Hiremath GS, Hameed F, Pacheco A, et al. Esophageal Food impaction and eosinophilic esophagitis: a retrospective study, systematic review, and metaanalysis. Dig Dis Sci. 2015;60(11):3181– 3193. doi: https://doi.org/10.1007/s10620-015-3723-8

70. Gretarsdottir HM, Jonasson JG, Bjornsson ES. Etiology and management of esophageal food impaction: a population based study. Scand J Gastroenterol. 2015;50(5):513–518. doi: https://doi.org/10.3109/00365521.2014.983159

71. Gonzalez Ayerbe JI, Hauser B, Salvatore S, Vandenplas Y. Diagnosis and Management of Gastroesophageal Reflux Disease in Infants and Children: from Guidelines to Clinical Practice. Pediatr Gastroenterol Hepatol Nutr. 2019;22(2):107–121. doi: https://doi.org/10.5223/pghn.2019.22.2.107

72. Iwakiri K, Fujiwara Y, Manabe N, et al. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022;57(4):267–285. doi: https://doi.org/10.1007/s00535-022-01861-z

73. Campora M, Mastracci L, Carlin L, et al. Pathologist’s approach to paediatric and neonatal eosinophilic gastrointestinal disorders. Pathologica. 2022;114(1):79–88. doi: https://doi.org/10.32074/1591-951X-734

74. Zand Irani M, Talley NJ, Ronkainen J, et al. Neutrophils, eosinophils, and intraepithelial lymphocytes in the squamous esophagus in subjects with and without gastroesophageal reflux symptoms. Hum Pathol. 2021;115:112–122. doi: https://doi.org/10.1016/j.humpath.2021.06.004

75. Binkovitz LA, Lorenz EA, Di Lorenzo C, Kahwash S. Pediatric eosinophilic esophagitis: radiologic findings with pathologic correlation. Pediatr Radiol. 2010;40(5):714–719. doi: https://doi. org/10.1007/s00247-009-1484-2

76. Sodikoff J, Hirano I. Proton pump inhibitor-responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis. J Allergy Clin Immunol. 2016;137(2):631–633. doi: https://doi.org/10.1016/j.jaci.2015.07.008

77. Visaggi P, Ghisa M, Marabotto E, et al. Esophageal dysmotility in patients with eosinophilic esophagitis: pathogenesis, assessment tools, manometric characteristics, and clinical implications. Esophagus. 2023;20(1):29–38. doi: https://doi.org/10.1007/S10388-022-00964-z

78. Lucendo AJ, Arias A, Gonzalez-Cervera J, et al. Dual response to dietary/topical steroid and proton pump inhibitor therapy in adult patients with eosinophilic esophagitis. J Allergy Clin Immunol. 2016;137(3):931–934.e2. doi: https://doi.org/10.1016/j.jaci.2015.07.033

79. Sicherer S. Allergy testing in eosinophilic esophagitis. November 2025. In: UpToDate: Website. Available online: https://www.uptodate.com/contents/allergy-testing-in-eosinophilic-esophagitis?search=Spergel&source=search_result&selectedTitle=1~3&usage_type=default&display_rank=1&searchCorrelationId=b5ea3b2bb0cb-439e-8ba0-52ded46945a5&searchCorrelationTerm=Sperg el. Accessed on July 08, 2026.

80. Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145(6):1230–1232.e1–e2. doi: https://doi.org/10.1053/j.gastro.2013.08.015

81. Lipka S, Kumar A, Richter JE. Impact of diagnostic delay and other risk factors on eosinophilic esophagitis phenotype and esophageal diameter. J Clin Gastroenterol. 2016;50(2):134–140. doi: https://doi.org/10.1097/MCG.0000000000000297

82. Warners MJ, Oude Nijhuis RAB, de Wijkerslooth LRH, et al. The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort. Am J Gastroenterol 2018;113:836–844. doi: https://doi.org/10.1038/S41395-018-0052-5

83. Mayerhofer C, Kavallar AM, Aldrian D, et al. Efficacy of Elimination Diets in Eosinophilic Esophagitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;21(9):2197–2210.e3. doi: https://doi.org/10.1016/j.cgh.2023.01.019

84. Cotton CC, Eluri S, Wolf WA, Dellon ES. Six-Food Elimination Diet and Topical Steroids are Effective for Eosinophilic Esophagitis: A Meta-Regression. Dig Dis Sci. 2017;62(9):2408–2420. doi: https://doi.org/10.1007/s10620-017-4642-7

85. Arias Á, Tejera-Muñoz A, Gutiérrez-Ramírez L, et al. Efficacy of Dietary Therapy for Eosinophilic Esophagitis in Children and Adults: An Updated Systematic Review and Meta-Analysis. Nutrients. 2024;16(14):2231. doi: https://doi.org/10.3390/nu16142231

86. Кайбышева В.О., Федоров Е.Д., Шаповальянц С.Г. Лечение эозинофильного эзофагита: обзор литературы и описание собственных клинических наблюдений // Российский аллергологический журнал. — 2025. — Т. 22. — № 1. — С. 23-43. — doi: https://doi.org/10.36691/RJA17001

87. Kagalwalla AF, Shah A, Li BUK, et al. Identification of specific foods responsible for inflammation in children with eosinophilic esophagitis successfully treated with empiric elimination diet. J Pediatr Gastroenterol Nutr. 2011;53(2):145–149. doi: https://doi.org/10.1097/MPG.0b013e31821cf503

88. Gonsalves N, Yang GY, Doerfler B, et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology. 2012;142:1451– 1459.e1; quiz e14–e15. doi: https://doi.org/10.1053/j.gastro.2012.03.001

89. Lucendo AJ, Arias A, Gonzalez-Cervera J, et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol. 2013;131(3):797–804. doi: https://doi.org/10.1016/j.jaci.2012.12.664

90. Arias A, Gonzalez-Cervera J, Tenias JM, et al. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014;146(7):1639–1648. doi. https://doi.org/10.1053/j.gastro.2014.02.006

91. Spergel JM, Beausoleil JL, Mascarenhas M, et al. The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol. 2002;109(2):363–368. doi: https://doi.org/10.1067/mai.2002.121458

92. Spergel JM, Brown-Whitehorn TF, Cianferoni A, et al. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. J Allergy Clin Immunol. 2012;130(2):461– 467.e5. doi: https://doi.org/10.1016/j.jaci.2012.05.021

93. Molina-Infante J, Martin-Noguerol E, Alvarado-Arenas M, et al. Selective elimination diet based on skin testing has suboptimal efficacy for adult eosinophilic esophagitis. J Allergy Clin Immunol. 2012;130(5):1200–1202. doi: https://doi.org/10.1016/j.jaci.2012.06.027

94. Philpott H, Nandurkar S, Royce SG, et al. Allergy tests do not predict food triggers in adult patients with eosinophilic oesophagitis. A comprehensive prospective study using five modalities. Aliment Pharmacol Ther. 2016;44(33):223–233. doi: https://doi.org/10.1111/apt.13676

95. Cotton CC, Erim D, Eluri S, et al. Cost utility analysis of topical steroids compared with dietary elimination for treatment of eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15(6):841– 849. doi: https://doi.org/10.1016/j.cgh.2016.11.032

96. Wolf WA, Jerath MR, Sperry SLW, et al. Dietary elimination therapy is an effective option for adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014;12(8):1272–1279. doi: https://doi.org/10.1016/j.cgh.2013.12.034

97. Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2006;4(9):1097–1102. doi: https://doi.org/10.1016/j.cgh.2006.05.026

98. Henderson CJ, Abonia JP, King EC, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2012;129(6):1570–1578. doi: https://doi.org/10.1016/j.jaci.2012.03.023

99. Molina-Infante J, Arias A, Barrio J, et al. Four-food group elimination diet for adult eosinophilic esophagitis: A prospective multicenter study. J Allergy Clin Immunol. 2014;134(5):1093–1099.e1. doi: https://doi.org/10.1016/j.jaci.2014.07.023

100. Molina-Infante J, Arias Á, Alcedo J, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study. J Allergy Clin Immunol. 2018;141(4):1365–1372. doi: https://doi.org/10.1016/j.jaci.2017.08.038

101. Kagalwalla A, Amsden K, Makhija MM, et al. A multicenter study assessing the clinical, endoscopic and histologic response to four food elimination diet for the treatment of eosinophilic esophagitis. Gastroenterology. 2015;148(Suppl 1):S-30.

102. Hirano E, Chan S, Rank M, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology. 2020;158(6):1776–1786. doi: https://doi.org/10.1053/j.gastro.2020.02.038

103. Kagalwalla AF, Amsden K, Shah A, et al. Cow’s milk elimination: a novel dietary approach to treat eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2012;55(6):711–716. doi: https://doi.org/10.1097/MPG.0b013e318268da40

104. Kruszewski PG, Russo JM, Franciosi JP, et al. Prospective, comparative effectiveness trial of cow’s milk elimination and swallowed fluticasone for pediatric eosinophilic esophagitis. Dis Esophagus. 2016;29(4):377–384. doi: https://doi.org/10.1111/dote.12339

105. Khokhar D, Marella S, Idelman G, et al. Eosinophilic esophagitis: Immune mechanisms and therapeutic targets. Clin Exp Allergy. 2022;52(10):1142–1156. doi: https://doi.org/10.1111/cea.14196

106. Wechsler JB, Schwartz S, Arva NC, et al. A Single-Food Milk Elimination Diet Is Effective for Treatment of Eosinophilic Esophagitis in Children. Clin Gastroenterol Hepatol. 2022;20(8):1748–1756. e11. doi: https://doi.org/10.1016/j.cgh.2021.03.049

107. Warners MJ, Vlieg-Boerstra BJ, Verheij J, et al. Elemental diet decreases inflammation and improves symptoms in adult eosinophilic oesophagitis patients. Aliment Pharmacol Ther. 2017;45(6):777– 787. doi: https://doi.org/10.1111/apt.13953

108. Peterson KA, Boynton KK. Which patients with eosinophilic esophagitis (EoE) should receive elemental diets versus other therapies? Curr Gastroenterol Rep. 2014;16(1):364. doi: https://doi.org/10.1007/s11894-013-0364-y

109. Peterson KA, Byrne KR, Vinson LA, et al. Elemental diet induces histologic response in adult eosinophilic esophagitis. Am J Gastroenterol. 2013;108(5):759–766. doi: https://doi.org/10.1038/ajg.2012.468

110. Groetch M, Venter C, Skypala I, et al. Dietary therapy and nutrition management of eosinophilic esophagitis: a work group report of the American Academy of allergy, asthma, and immunology. J Allergy Clin Immunol. 2017;5(2):312–324. doi: https://doi.org/10.1016/j.jaip.2016.12.026

111. Cianferoni A, Shuker M, Brown-Whitehorn T, et al. Food avoidance strategies in eosinophilic oesophagitis. Clin Exp Allergy. 2019;49(3):269–284. doi: https://doi.org/10.1111/cea.13360

112. Sova C, Feuling MB, Baumler M, et al. Systematic review of nutrient intake and growth in children with multiple IgE-mediated food allergies. Nutr Clin Pract. 2013;28(6):669–675. doi: https://doi.org/10.1177/0884533613505870

113. Lucendo AJ, Molina-Infante J. Dietary therapy for eosinophilic esophagitis: chances and limitations in the clinical practice. Expert Rev Gastroenterol Hepatol. 2020;14(10):941–952. doi: https://doi.org/10.1080/17474124.2020

114. Moawad FJ, Veerappan GR, Dias JA, et al. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol. 2013;108(3):366–372. doi: https://doi.org/10.1038/ajg.2012.443

115. Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(1):13–22. doi: https://doi.org/10.1016/j.cgh.2015.07.041

116. Peterson KA, Thomas KL, Hilden K, et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig Dis Sci. 2010;55(5):1313–1319. doi: https://doi.org/10.1007/s10620-009-0859-4

117. Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2013;62(6):824–832. doi: https://doi.org/10.1136/gutjnl-2012-302250

118. Ngo P, Furuta GT, Antonioli DA, et al. Eosinophils in the esophagus--peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol. 2006;101(7):1666–1670. doi: https://doi.org/10.1111/j.1572-0241.2006.00562.x

119. Dranove JE, Horn DS, Davis MA, et al. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr. 2009;154(1):96–100. doi: https://doi.org/10.1016/j.jpeds.2008.07.042

120. Molina-Infante J, Ferrando-Lamana L, Ripoll C, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol. 2011;9(2):110–117. doi: https://doi.org/10.1016/j.cgh.2010.09.019

121. Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, et al. High prevalence of response to proton-pump inhibitor treatment in children with esophageal eosinophilia. J Pediatr Gastroenterol Nutr. 2016;62(5):704–710. doi: https://doi.org/10.1097/MPG.0000000000001019

122. Cheng E, Zhang X, Wilson KS, et al. JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve Inflammation and Prevent Fibrosis in EoE. PLoS One. 2016;11(6):e0157376. doi: https://doi.org/10.1371/journal.pone.0157376

123. Dellon ES, Liacouras CA. Advances in clinical management of eosinophilic esophagitis. Gastroenterology. 2014;147(6):1238– 1254. doi: https://doi.org/10.1053/j.gastro.2014.07.055

124. Molina-Infante J, Rodriguez-Sanchez J, Martinek J, et al. Longterm loss of response in proton pump inhibitor-responsive esophageal eosinophilia is uncommon and influenced by CYP2C19 genotype and rhinoconjunctivitis. Am J Gastroenterol. 2015;110(11):1567–1575. doi: https://doi.org/10.1038/ajg.2015.314

125. Vazquez-Elizondo G, Ngamruengphong S, Khrisna M, et al. The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. Aliment Pharmacol Ther. 2013;38(10):1312–1319. doi: https://doi.org/10.1111/apt.12513

126. Dellon ES, Speck O, Woodward K, et al. Clinical and endoscopic characteristics do not reliably differentiate PPIresponsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. Am J Gastroenterol. 2013;108(12):1854–1860. doi: https://doi.org/10.1038/ajg.2013.363

127. Franciosi JP, Mougey EB, Dellon ES, et al. Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions. J Asthma Allergy. 2022;15:281–302. doi: https://doi.org/10.2147/JAA.S274524

128. Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, et al. Long-term treatment with proton pump inhibitors is effective in children with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2018;67(2):210–216. doi: https://doi.org/10.1097/MPG.0000000000001952

129. Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol. 2008;6(2):165–173. doi: https://doi.org/10.1016/j.cgh.2007.11.008

130. Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2012;10(7):742– 749. doi: https://doi.org/10.1016/j.cgh.2012.03.018

131. Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13(1):66–76. doi: https://doi.org/10.1016/j.cgh.2014.05.021

132. Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology. 2010;139(2):418–429. doi: https://doi.org/10.1053/j.gastro.2010.05.001

133. Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, doubleblind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology. 2006;131(5):1381– 1391. doi: https://doi.org/10.1053/j.gastro.2006.08.033

134. Dellon ES, Sheikh A, Speck O, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology. 2012;143(2):321–324. doi: https://doi.org/10.1053/j.gastro.2012.04.049

135. Butz BK, Wen T, Gleich GJ, et al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology. 2014;147(2):324–333. doi: https://doi.org/10.1053/j.gastro.2014.04.019

136. Miehlke S, Hruz P, Vieth M, et al. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut. 2016;65(3):390–399. doi: https://doi.org/10.1136/gutjnl-2014-308815

137. Tan ND, Xiao YL, Chen MH. Steroids therapy for eosinophilic esophagitis: Systematic review and meta-analysis. J Dig Dis. 2015;16(8):431–442. doi: https://doi.org/10.1111/1751-2980.12265

138. Sawas T, Dhalla S, Sayyar M, et al. Systematic review with meta-analysis: pharmacological interventions for eosinophilic oesophagitis. Aliment Pharmacol Ther. 2015;41(9):797–806. doi: https://doi.org/10.1111/apt.13147

139. Murali AR, Gupta A, Attar BM, et al. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo controlled randomized clinical trials. J Gastroenterol Hepatol. 2015;31(6):1111–1119. doi: https://doi.org/10.1111/jgh.13281

140. Chuang MY, Chinnaratha MA, Hancock DG, et al. Topical steroid therapy for the treatment of eosinophilic esophagitis (EoE): a systematic review and meta-analysis. Clin Transl Gastroenterol. 2015;6(3):e82. doi: https://doi.org/10.1038/ctg.2015.9

141. Straumann A, Conus S, Degen L, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2011;9(5):400–409. doi: https://doi.org/10.1016/j.cgh.2011.01.017

142. Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am J Gastroenterol. 2007;102(10):2271–2279; quiz 2280. doi: https://doi.org/10.1111/j.1572-0241.2007.01379.x

143. Bonis PAL, Gupta SK. Treatment of eosinophilic esophagitis (EoE). May 27, 2026. In: UpToDate: Website. Available online: https://www.uptodate.com/contents/treatment-of-eosinophilicesophagitis-eoe/print. Accessed on July 08, 2026.

144. Dellon ES, Katzka DA, Collins MH, et al. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis. Gastroenterology. 2017;152(4):776–786.e5. doi: https://doi.org/10.1053/j.gastro.2016.11.021

145. Hirano I, Collins MH, Katzka DA, et al. Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial. Clin Gastroenterol Hepatol. 2022;20(3):525–534.e10. doi: https://doi.org/10.1016/j.cgh.2021.04.022

146. Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157(1):74–86. doi: https://doi.org/10.1053/j.gastro.2019.03.025

147. Straumann A, Lucendo AJ, Miehlke S, et al. Budesonide Orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020;159(5):1672–1685. doi: https://doi.org/10.1053/j.gastro.2020.07.039

148. Philla KQ, Min SB, Hefner JN, et al. Swallowed glucocorticoid therapy for eosinophilic esophagitis in children does not suppress adrenal function. J Pediatr Endocrinol Metab. 2015;28(9-10):1101– 1106. doi: https://doi.org/10.1515/jpem-2014-0260

149. Andreae DA, Hanna MG, Magid MS, et al. Swallowed fluticasone propionate is an effective long-term maintenance therapy for children with eosinophilic esophagitis. Am J Gastroenterol. 2016;111(8):1187– 1197. doi: https://doi.org/10.1038/ajg.2016.238

150. Golekoh MC, Hornung LN, Mukkada VA, et al. Adrenal insufficiency after chronic swallowed glucocorticoid therapy for eosinophilic esophagitis. J Pediatr. 2016;170:240–245. doi: https://doi.org/10.1016/j.jpeds.2015.11.026

151. Harel S, Hursh BE, Chan ES, et al. Adrenal suppression in children treated with oral viscous budesonide for eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2015;61(2):190–193. doi: https://doi.org/10.1097/MPG.0000000000000848

152. Tomizawa Y, Melek J, Komaki Y, et al. Efficacy of Pharmacologic Therapy for Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis. J Clin Gastroenterol. 2018;52(7):596–606. doi: https://doi.org/10.1097/MCG.0000000000000878

153. Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE). In: ClinicalTrials.gov: Website. Available online: https://clinicaltrials.gov/ct2/show/NCT03633617. Accessed on July 08, 2026.

154. Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med. 2022;387(25):2317–2330. doi: https://doi.org/10.1056/NEJMoa2205982

155. Chehade M, Dellon ES, Spergel JM, et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024;390(24):2239–2251. doi: https://doi.org/10.1056/NEJMoa2312282

156. Zuo L, Fulkerson PC, Finkelman FD, et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13Rα2-inhibited pathway. J Immunol. 2010;185(1):660– 669. doi: https://doi.org/10.4049/jimmunol.1000471

157. Doran E, Cai F, Holweg CTJ, et al. Interleukin-13 in Asthma and Other Eosinophilic Disorders. Front Med (Lausanne). 2017;4:139. doi: https://doi.org/110.3389/fmed.2017.00139

158. Davis BP, Stucke EM, Khorki ME, et al. Eosinophilic esophagitis-linked calpain 14 is an IL-13-induced protease that mediates esophageal epithelial barrier impairment. JCI Insight. 2016;1(4):86355. doi: https://doi.org/10.1172/jci.insight.86355

159. Rothenberg ME, Wen T, Greenberg A, et al. Intravenous antiIL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015;135(2):500–507. doi https://doi.org/10.1016/j.jaci.2014.07.049.

160. Blanchard C, Mishra A, Saito-Akei H, et al. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy. 2005;35(8):1096–1103. doi: https://doi.org/10.1111/j.1365-2222.2005.02299.x

161. Spergel BL, Ruffner MA, Godwin BC, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022;128(5):589–593. doi: https://doi.org/10.1016/j.anai.2022.01.019

162. Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients with Active Eosinophilic Esophagitis (EoE) (EoE KIDS). In: ClinicalTrials.gov: Website. Available online: https://clinicaltrials.gov/ct2/show/NCT04394351. Accessed on July 08, 2026.

163. Straumann A, Bauer M, Fischer B, et al. Idiopathic eosinophilic esophagitis is associated with a Th2-type allergic inflammatory response. J Allergy Clin Immunol. 2001;108(6):954–961. doi: https://doi.org/10.1067/mai.2001.119917

164. O’Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol. 2001;108(4):503–508. doi: https://doi.org/10.1067/mai.2001.119149

165. Mishra A, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology. 2003;125(5):1419–1427. doi: https://doi.org/10.1016/j.gastro.2003.07.007

166. Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59(1):21–30. doi: https://doi.org/10.1136/gut.2009.178558

167. Assa’ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141(5):1593– 1604. doi: https://doi.org/10.1053/j.gastro.2011.07.044

168. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(2):456–463. doi: https://doi.org/10.1016/j.jaci.2011.11.044

169. Rothenberg ME, Dellon ES, Collins MH, et al. Efficacy and safety of benralizumab in adults and adolescents with eosinophilic esophagitis: results from the 24-week double-blind period of the phase 3 MESSINA trial. Gastroenterology. 2023;164(6):S-115. doi: https://doi.org/10.1016/S0016-5085(23)01239-8

170. Dellon ES, Spergel JM. Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023;130(1):21–27. doi: https://doi.org/10.1016/j.anai.2022.06.015

171. Tamarit-Sebastian S, Ferrer-Soler FM, Lucendo AJ. Current options and investigational drugs for the treatment of eosinophilic esophagitis. Expert Opin Investig Drugs. 2022;31(2):193–210. doi: https://doi.org/10.1080/13543784.2022.2033207

172. A Study of Benralizumab in Patients With Eosinophilic Esophagitis (MESSINA). In: ClinicalTrials.gov: Website. Available online: https://clinicaltrials.gov/study/NCT04543409. Accessed on July 08, 2026.

173. Netzer P, Gschossmann JM, Straumann A, et al. Corticosteroiddependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol. 2007;19(10):865–869. doi: https://doi.org/10.1097/MEG.0b013e32825a6ab4

174. Abonia JP, Blanchard C, Butz BB, et al. Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol. 2010;126(1):140–149. doi: https://doi.org/10.1016/j.jaci.2010.04.009

175. Arias A, Lucendo AJ, Martinez-Fernandez P, et al. Dietary treatment modulates mast cell phenotype, density, and activity in adult eosinophilic oesophagitis. Clin Exp Allergy. 2016;46(1):78–91. doi: https://doi.org/10.1111/cea.12504

176. Liacouras CA, Spergel JM, Ruchelli E, et al. Eosinophilic esophagitis: A 10-year experience in 381 children. Clin Gastroenterol Hepatol. 2005;3(12):1198–1206. doi: https://doi.org/10.1016/S1542-3565(05)00885-2

177. Attwood SEA, Lewis CJ, Bronder CS, et al. Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut. 2003;52(2):181–185. doi: https://doi.org/10.1136/gut.52.2.18

178. Stumphy J, Al-Zubeidi D, Guerin L, et al. Observations on use of montelukast in pediatric eosinophilic esophagitis: insights for the future. Dis Esophagus. 2011;24(4):229–234. doi: https://doi.org/10.1111/j.1442-2050.2010.01134.x

179. Alexander JA, Ravi K, Enders FT, et al. Montelukast Does not Maintain Symptom Remission After Topical Steroid Therapy for Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2017;15(2):214–221.e2. doi: https://doi.org/10.1016/j.cgh.2016.09.013

180. Lucendo AJ, De Rezende LC, Jimenez-Contreras S, et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci. 2011;56(12):3551– 3558. doi: https://doi.org/10.1007/s10620-011-1775-y

181. Moawad FJ, Cheatham JG, DeZee KJ. Meta-analysis: the safety and efficacy of dilation in eosinophilic oesophagitis. Aliment Pharmacol Ther. 2013;38(7):713–720. doi: https://doi.org/10.1111/apt.12438